Johnson & Johnson pauses COVID-19 vaccine clinical trials
Drug maker Johnson & Johnson Oct. 12 announced the pause of its large-scale, pivotal, multi-country phase 3 trial for its JNJ-78436735 COVID-19 vaccine candidate. The pause is the result of an unexplained illness in a study volunteer participant. Johnson & Johnson announced the start of its phase 3 trial for the Janssen Pharmaceutical Companies-developed vaccine on Sept. 23.
Related News Articles
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…